<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 19, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01790061</url>
  </required_header>
  <id_info>
    <org_study_id>FMT-CN-121123</org_study_id>
    <nct_id>NCT01790061</nct_id>
  </id_info>
  <brief_title>Standardized Fecal Microbiota Transplantation for Ulcerative Colitis</brief_title>
  <official_title>Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation in Patients With Moderate to Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second Hospital of Nanjing Medical University</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gut microbiota is considered to constitute a &quot;microbial organ&quot; which has pivotal roles
      in the intestinal diseases and body's metabolism. Evidence from animal and human studies
      strongly supports the link between intestinal bacteria and inflammatory bowel diseases
      (IBD). Dozens of studies reported its efficacy in treatment of severe Clostridium difficile
      colitis. Preliminary studies using FMT for Ulcerative Colitis (UC), Crohn's diseases,
      irritable bowel syndrome (IBS) and constipation have also met with some success. This is an
      initial step into investigating the potential efficacy of standardized fecal bacteriotherapy
      through mid-gut (at least below duodenal papilla) for UC, the investigators propose to
      determine the efficiency and safety of FMT in a series of 60 patients with moderate to
      severe UC (Montreal classification).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present clinical trial aims to re-establish a gut functionality state of intestinal
      flora through FMT as a therapy for UC. Investigators established a standard bacteria
      isolation from donated fresh stool in lab. Then the bacteria is transplanted to mid-gut
      through regular gastroscope. Patients in this study will assigned to receive FMT only once
      or traditional treatments according to associated guidelines and follow-up for at least one
      year. Blood tests , endoscopy and questionnaire will be used to assess participants at study
      start and at study completion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>durability of clinical remission</measure>
    <time_frame>One month</time_frame>
    <safety_issue>No</safety_issue>
    <description>The durability of clinical remission (days) after Fecal Microbiota Transplantation procedure.Defined as Montreal score S0 (clinical remission)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients with worsened disease</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with worsened disease. Increase in Montreal score S1, S2 and S3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bacteria</condition>
  <condition>Flora</condition>
  <condition>Fecal Microbiota Transplantation</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Standardized Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standardized Fecal Microbiota Transplantation, once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional treatments</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Traditional treatments according to associated guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standardized Fecal Microbiota Transplantation</intervention_name>
    <description>Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut (below the second part of duodenum).</description>
    <arm_group_label>Standardized Fecal Microbiota Transplantation</arm_group_label>
    <other_name>Fecal Microbiota Transplantation</other_name>
    <other_name>Fecal Microbiota Therapy</other_name>
    <other_name>fecal transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traditional treatments according to associated guidelines</intervention_name>
    <description>Traditional treatments according to associated guidelines</description>
    <arm_group_label>Traditional treatments</arm_group_label>
    <other_name>Traditional treatments according to associated guidelines</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Mild to moderate UC (Montreal classification)

        Exclusion Criteria:

        Diagnosed as UC first time. No history of using Biologic,immunomodulatory therapy or
        corticosteroid therapy.

        With contraindication of endoscopy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Faming Zhang, MD,PhD</last_name>
    <phone>086-25-58509883</phone>
    <email>fzhang@njmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faming Zhang, MD, PhD</last_name>
      <phone>086-25-58509883</phone>
      <email>fzhang@njmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed</url>
    <description>Fecal microbiota transplantation</description>
  </link>
  <reference>
    <citation>Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011 Dec 20;9(2):88-96. doi: 10.1038/nrgastro.2011.244. Review.</citation>
    <PMID>22183182</PMID>
  </reference>
  <reference>
    <citation>Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013 Jan;29(1):79-84. doi: 10.1097/MOG.0b013e32835a4b3e.</citation>
    <PMID>23041678</PMID>
  </reference>
  <reference>
    <citation>Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012 Nov;107(11):1755; author reply p.1755-6. doi: 10.1038/ajg.2012.251.</citation>
    <PMID>23160295</PMID>
  </reference>
  <reference>
    <citation>Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989 Jan 21;1(8630):164.</citation>
    <PMID>2563083</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 15, 2013</lastchanged_date>
  <firstreceived_date>February 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Hospital of Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Faming Zhang</investigator_full_name>
    <investigator_title>Associate professor, Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Gut bacteria</keyword>
  <keyword>Gut flora</keyword>
  <keyword>Bacteriotherapy</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Inflammatory bowel disease</keyword>
  <keyword>Ulcerative colitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
